Fujinaga Jun, Kuriyama Akira, Ikegami Tetsunori, Onodera Mutsuo
Emergency and Critical Care Center, Kurashiki Central Hospital, Kurashiki City, Okayama, Japan.
Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
J Emerg Trauma Shock. 2021 Jan-Mar;14(1):38-41. doi: 10.4103/JETS.JETS_17_20. Epub 2021 Mar 23.
The Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score helps to diagnose necrotizing soft-tissue infection (NSTI). The LRINEC score has been reported to be associated with poor prognosis, although few studies have evaluated this association.
We aimed to describe the characteristics of NSTI and assess whether the LRINEC score was associated with mortality and amputation.
We conducted a retrospective observational study from January 2007 to May 2018, in a Japanese tertiary care hospital.
Patients with NSTI were identified through our hospital database using the discharge diagnosis. We extracted data on patient characteristics, laboratory examinations, microbiological information, treatment, and in-hospital mortality.
We estimated the odds ratios (ORs) and associated 95% confidence intervals (CIs) for in-hospital mortality using logistic regression models.
We identified 58 patients. The median LRINEC score was 8 (interquartile range [IQR]: 6-9). Forty-four patients (75.9%) scored 6 or more. The eight patients with amputations had a median score of 6 (IQR: 4.5-7.5) versus 8 (IQR: 7-9) for patients who underwent debridement ( = 0.091). Survivors and nonsurvivors had median scores of 8 (IQR: 6-9) and 6 (IQR: 5-8), respectively ( = 0.148). The OR for mortality in patients with liver cirrhosis was 10.5 (95% CI: 1.00-110.36; = 0.050).
There was no association between the LRINEC score and patients' outcomes: mortality and amputation. Further studies are warranted to evaluate the utility of the LRINEC score and factors associated with poor prognosis in patients with NSTI.
坏死性筋膜炎实验室风险指标(LRINEC)评分有助于诊断坏死性软组织感染(NSTI)。尽管很少有研究评估这种关联,但据报道LRINEC评分与预后不良有关。
我们旨在描述NSTI的特征,并评估LRINEC评分是否与死亡率和截肢相关。
我们于2007年1月至2018年5月在一家日本三级护理医院进行了一项回顾性观察研究。
通过医院数据库利用出院诊断确定NSTI患者。我们提取了患者特征、实验室检查、微生物学信息、治疗及院内死亡率的数据。
我们使用逻辑回归模型估计院内死亡率的比值比(OR)及相关的95%置信区间(CI)。
我们确定了58例患者。LRINEC评分的中位数为8(四分位间距[IQR]:6 - 9)。44例患者(75.9%)评分在6分及以上。8例行截肢手术的患者评分中位数为6(IQR:4.5 - 7.5),而行清创术的患者评分中位数为8(IQR:7 - 9)(P = 0.091)。存活者和非存活者的评分中位数分别为8(IQR:6 - 9)和6(IQR:5 - 8)(P = 0.148)。肝硬化患者的死亡OR为10.5(95%CI:1.00 - 110.36;P = 0.050)。
LRINEC评分与患者结局(死亡率和截肢)之间无关联。有必要进一步研究评估LRINEC评分的效用以及NSTI患者预后不良的相关因素。